Clinical trials: Pleomorphic Liposarcoma
Soft Tissue Sarcoma (Excluding GIST), Soft Tissue Sarcoma Adult
Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma
The purpose of the study is to investigate whether a personalized selection of patients with localized soft tissue sarcoma for preoperative proton radiation therapy can reduce long-term radiation side effects without increasing…
- Conditions
- Soft Tissue Sarcoma (Excluding GIST), Soft Tissue Sarcoma Adult, Soft Tissue Sarcoma of the Trunk and Extremities, Synovial Sarcomas
- Trial name
- PROSARC-1 (NCT07169344)
- Testing
- preoperative, Quality of life, Functional outcome
- Where
- 4 sites in Norway
- Volunteers
- 110 people
- Sponsor
- Oslo University Hospital
Soft Tissue Sarcoma
APX005M and Doxorubicin in Advanced Sarcoma
This phase II clinical trial will evaluate the safety and efficacy of adding APX005M (a CD40 agonistic monoclonal antibody) to doxorubicin for the treatment of patients with advanced soft tissue sarcoma.
- Trial name
- NCT03719430
- Testing
- Doxorubicin, APX005M
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Alexander Z. Wei, MD
Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
This phase II trial compares the effect of immunotherapy with ipilimumab and nivolumab alone to their combination with cabozantinib in treating patients with soft tissue sarcoma that has spread from where it first started to…
- Conditions
- Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma, Locally Advanced Undifferentiated Pleomorphic Sarcoma
- Trial name
- NCT05836571
- Testing
- Biopsy Procedure, Biospecimen Collection, Cabozantinib
- Where
- 27 sites in United States, Canada
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute LAO
Dedifferentiated Liposarcoma
Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma
Randomized, multicenter, open-label, Phase 3 registration study designed to evaluate the safety and efficacy of milademetan compared to trabectedin in patients with unresectable (i.e., where resection is deemed to cause…
- Trial name
- MANTRA (NCT04979442)
- Testing
- RAIN-32, Trabectedin
- Where
- 71 sites in United States, Austria and 13 more
- Volunteers
- 175 people
- Sponsor
- Rain Oncology Inc
Leiomyosarcoma, Liposarcoma
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
This study will evaluate the safety and efficacy of MASCT-I combined with Doxorubicin and Ifosfamide for first-line treatment in patients with advanced soft tissue sarcoma.
- Conditions
- Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Angiosarcoma
- Trial name
- NCT06277154
- Testing
- MASCT-I, Doxorubicin, Ifosfamide
- Where
- China
- Volunteers
- 148 people
- Sponsor
- HRYZ Biotech Co.
Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
This randomized phase II/III trial studies how well pazopanib, when combined with chemotherapy and radiation therapy or radiation therapy alone, work in the treatment of patients with newly diagnosed non-rhabdomyosarcoma soft…
- Conditions
- Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma, Clear Cell Sarcoma of Soft Tissue
- Trial name
- NCT02180867
- Testing
- Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide
- Where
- 381 sites in United States, Canada and 1 more
- Volunteers
- 140 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma, Soft Tissue, Soft Tissue Sarcoma
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
The purpose of this research study is to look at whether giving a drug called dexrazoxane with standard of care doxorubicin affects the progression of the disease.
- Conditions
- Sarcoma, Soft Tissue, Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma
- Trial name
- NCT02584309
- Testing
- Dexrazoxane, Doxorubicin
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Washington University School of Medicine
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have…
- Trial name
- NCT00031915
- Testing
- imatinib mesylate
- Where
- 10 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Uveal Melanoma, Melanoma
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma
This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma.
- Conditions
- Uveal Melanoma, Melanoma, Metastatic Uveal Melanoma, Metastatic Melanoma
- Trial name
- NCT05607095
- Testing
- Lifileucel (LN-144/LN-145)
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Sarcoma, Soft Tissue
The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma
This is a phase II trial to explore the feasibility of PD-1 immune check point inhibitor, sintilimab, in combination of stand of care chemotherapy in first-line treatment of selected soft tissue sarcoma.
- Trial name
- NCT04356872
- Testing
- Sintilimab, Doxorubicin Hydrochloride, Ifosfamide
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Fudan University
Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
This phase Ib trial studies the side effects and best dose of ribociclib when giving together with doxorubicin hydrochloride in treating patients with soft tissue sarcomas that has spread to other places or that cannot be removed…
- Conditions
- Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma
- Trial name
- NCT03009201
- Testing
- Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- OHSU Knight Cancer Institute
Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
This randomized phase I/II clinical trial is studying the side effects and best dose of gamma-secretase/notch signalling pathway inhibitor RO4929097 when given together with vismodegib and to see how well they work in treating…
- Conditions
- Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma
- Trial name
- NCT01154452
- Testing
- Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
Adult Pleomorphic Rhabdomyosarcoma, AJCC Grade 2 Sarcoma
Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma
This phase III trial compares chest computed tomography (CT) to chest x-ray (CXR) for lung surveillance after curative-intent resection of high-risk truncal-extremity soft tissue sarcoma.
- Conditions
- Adult Pleomorphic Rhabdomyosarcoma, AJCC Grade 2 Sarcoma, AJCC Grade 3 Sarcoma, Alveolar Soft Part Sarcoma
- Trial name
- NCT06526897
- Testing
- Biopsy, Chest Computed Tomography, Chest Radiography
- Volunteers
- 1,582 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Soft Tissue Sarcomas, Angiosarcoma
IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
This study will enroll patients with specific subtypes of unresectable or metastatic soft tissue sarcoma, and will combine tislelizumab with the standard chemotherapy of liposomal doxorubicin and ifosfamide to initially explore…
- Conditions
- Soft Tissue Sarcomas, Angiosarcoma, Fibrosarcoma, Leiomyosarcoma
- Trial name
- TAIS (NCT06849986)
- Testing
- Tislelizumab+liposomal doxorubicin+ifosfamide
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Fudan University
Leiomyosarcoma, Liposarcoma
Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
This phase II trial studies the side effects of talimogene laherparepvec and radiation therapy and to see how well they work in treating patients with newly diagnosed soft tissue sarcoma that can be removed by surgery…
- Conditions
- Leiomyosarcoma, Liposarcoma, Sarcoma G2, Sarcoma G3
- Trial name
- NCT02923778
- Testing
- Biopsy Procedure, Biospecimen Collection, Magnetic Resonance Imaging
- Where
- 17 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Resectable Liposarcoma, Resectable Soft Tissue Sarcoma
Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall
This phase III trial compares the effect of adding doxorubicin and ifosfamide (AIM chemotherapy) before (neoadjuvant) receiving standard treatment with pembrolizumab, radiation therapy and surgery to standard of care treatment…
- Conditions
- Resectable Liposarcoma, Resectable Soft Tissue Sarcoma, Resectable Undifferentiated Pleomorphic Sarcoma
- Trial name
- NCT07823491
- Testing
- Biospecimen Collection, Computed Tomography, Doxorubicin
- Where
- United States
- Volunteers
- 228 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Leiomyosarcoma, Pleomorphic Liposarcoma
Detection of Circulating Tumor Cells in Patients With Sarcomas
The sarcomas represent 1% of all cancers in adults, 8% in adolescents and young people, and 10% in children. Even though it is a rare cancer, it contributes to a significant loss of years of life in comparison with other types of…
- Conditions
- Leiomyosarcoma, Pleomorphic Liposarcoma, Synovial Sarcoma, Liposarcoma
- Trial name
- CTCS (NCT02983539)
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- AC Camargo Cancer Center
Sarcoma, Alveolar Soft Part Sarcoma
Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas
After a screening, which consists of biopsy, physical examination, initial diffusion-weighted magnetic resonance imaging (DWI-MRI) or body computed tomography (CT) scan, blood tests and case analysis on Multidisciplinary Team…
- Conditions
- Sarcoma, Alveolar Soft Part Sarcoma, Clear Cell Sarcoma, Malignant Peripheral Nerve Sheath Tumors
- Trial name
- SINDIR (NCT03989596)
- Testing
- Hypofractionated radiotherapy, Hyperthermia
- Where
- Poland
- Volunteers
- 30 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Well Differentiated Liposarcoma, Dedifferentiated Liposarcoma
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
The purpose of this study is to find out whether mirdametinib in combination with palbociclib is an effective and safe treatment for people with metastatic, recurrent, and unresectable liposarcoma.
- Conditions
- Well Differentiated Liposarcoma, Dedifferentiated Liposarcoma, Liposarcoma, Myxoid Liposarcoma
- Trial name
- NCT06843967
- Testing
- Mirdametinib, Palbociclib
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adipocytic Neoplasm, Liposarcoma
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
The study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS). Primary Objectives Intermediate-Risk To estimate the 3-year event-free survival for intermediate-risk patients treated with ifosfamide, doxorubicin…
- Conditions
- Adipocytic Neoplasm, Liposarcoma, Atypical Fibroxanthoma, Angiomatoid Fibrous Histiocytoma
- Trial name
- NCT06239272
- Testing
- Surgical resection, Proton beam radiation therapy, Pazopanib
- Where
- 7 sites in United States
- Volunteers
- 139 people
- Sponsor
- St. Jude Children's Research Hospital